Acquisitions and Divestiture - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		12 Months Ended			0 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 01, 2013	Aug. 29, 2013	Oct. 10, 2014	Dec. 16, 2011	Oct. 01, 2013	Nov. 14, 2013	Jul. 29, 2013	Oct. 19, 2012
Significant Acquisitions and Disposals [Line Items]
Acquisition costs, integration costs	$ 11.2		$ 2.3	$ 11.3	$ 2.1
Payments made for intangibles			13.3	33.9	19.4
Divestiture of business in cash			0	267.4	0
Gain on sale of BEP	213.0		0	213.0	0
Divestiture-related charges	7.8	9.7	0	17.5	0
Severance cost			7.5
Electrophysiology Division (BEP)
Significant Acquisitions and Disposals [Line Items]
Remaining liability related to restructuring charge			1.5
Divestiture of business in cash						267.4
Gain on sale of BEP						213.0
Gain on sale of BEP, after tax						118.5
Derecognition of goodwill						38.9
Divestiture-related charges				17.5
Divestiture-related charges, after tax				12.2
Severance cost				6.7
Severance costs, after tax				5.2
Electrophysiology Division (BEP) | Maximum
Significant Acquisitions and Disposals [Line Items]
Manufacturing and other transition services contract term						5 years
Technology
Significant Acquisitions and Disposals [Line Items]
Payments made for intangibles							29.5
Contingent payments for intangibles							5.0
Lutonix, Inc.
Significant Acquisitions and Disposals [Line Items]
Business acquisition purchase price									298.0
Business acquisition, maximum contingent consideration									100
Business acquisition, purchase consideration cash payment									228.0
Fair value of contingent consideration	73			73					70
Probability of payment of contingent consideration	75.00%			75.00%
Contingent milestone payment								100
Medafor, Inc.
Significant Acquisitions and Disposals [Line Items]
Percentage of outstanding stock acquired										100.00%
Business acquisition purchase price										206.3
Purchase price allocation at fair value, recognition of deferred tax liabilities										61.4
Purchase price allocation at fair value, recognition of deferred tax assets										10.9
Purchase price allocation at fair value, other asset										11.3
Purchase price allocation at fair value, goodwill										80.3
Acquisition related transaction costs										2.2
Acquisition costs, integration costs										4.1
Acquisition costs, integration costs, after tax										2.6
Business acquisition, maximum contingent consideration										80
Business acquisitions, contingent consideration payable, through date										Jun. 30, 2015
Medafor, Inc. | In-Process Research And Development
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset										79.6
Risk-adjusted discount rate										16.00%
Medafor, Inc. | Developed technologies
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset										85.6
Estimated useful lives, years										10 years
Rochester Medical, Inc.
Significant Acquisitions and Disposals [Line Items]
Percentage of outstanding stock acquired											100.00%
Business acquisition purchase price											262.3
Purchase price allocation at fair value, recognition of deferred tax liabilities											63.1
Purchase price allocation at fair value, Cash											26.0
Purchase price allocation at fair value, plant and equipment											21.7
Purchase price allocation at fair value, recognition of deferred tax assets											9.4
Purchase price allocation at fair value, other asset											4.7
Purchase price allocation at fair value, goodwill											84.1
Acquisition related transaction costs											1.9
Acquisition costs, integration costs											7.1
Acquisition costs, integration costs, after tax											4.6
Remaining liability related to restructuring charge			1.0
Rochester Medical, Inc. | In-Process Research And Development
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset											7.6
Risk-adjusted discount rate											14.00%
Rochester Medical, Inc. | Other Intangible Assets
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset											26.8
Estimated useful lives, years											14 years
Rochester Medical, Inc. | Developed technologies
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset											145.1
Estimated useful lives, years											14 years
Loma Vista Medical, Inc.
Significant Acquisitions and Disposals [Line Items]
Percentage of outstanding stock acquired												100.00%
Business acquisition purchase price												39.4
Purchase price allocation at fair value, recognition of deferred tax liabilities												14.8
Purchase price allocation at fair value, goodwill												8.6
Business acquisition, maximum contingent consideration												8
Business acquisition, purchase consideration cash payment												32.5
Purchase price allocation at fair value, other asset												4.8
Loma Vista Medical, Inc. | In-Process Research And Development
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset												20.2
Risk-adjusted discount rate												27.00%
Loma Vista Medical, Inc. | Core Technologies
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset												20.6
Neomend, Inc.
Significant Acquisitions and Disposals [Line Items]
Percentage of outstanding stock acquired													100.00%
Business acquisition purchase price													133.7
Purchase price allocation at fair value, recognition of deferred tax liabilities													36.0
Purchase price allocation at fair value, recognition of deferred tax assets													27.0
Purchase price allocation at fair value, goodwill													52.4
Acquisition related transaction costs													1.3
Business acquisition, maximum contingent consideration													25
Business acquisition, contingent consideration payment due date													2016
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other													1.9
Neomend, Inc. | In-Process Research And Development
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset													29.4
Risk-adjusted discount rate													24.00%
Neomend, Inc. | Core Technologies
Significant Acquisitions and Disposals [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset													$ 62.8
Estimated useful lives, years													15 years